Chinese expert consensus on the management of hypertension in adults with type 2 diabetes

被引：1

作者：

Pan, Xiaohui ^{[1
]}

He, Hongbo ^{[2
,3
]}

Bao, Yuqian ^{[4
]}

Bi, Yan ^{[5
]}

Chen, Luyuan ^{[6
,7
]}

Chen, Xiaoping ^{[8
]}

Fang, Hui ^{[9
]}

Feng, Wenhuan ^{[5
]}

Gao, Ling ^{[10
]}

Guo, Lixin ^{[11
,12
,13
]}

Guo, Yifang ^{[14
]}

Han, Yaling ^{[15
,16
]}

Hua, Qi ^{[17
]}

Li, Nanfang ^{[18
]}

Li, Quanmin ^{[19
]}

Li, Yan ^{[20
,21
]}

Li, Yong ^{[22
]}

Li, Xialian ^{[23
]}

Liu, Jing ^{[24
]}

Ma, Huijuan ^{[25
]}

Mu, Jianjun ^{[26
]}

Nong, Kailei ^{[1
]}

Shang, Huiqian ^{[27
]}

Shen, Yunfeng ^{[28
]}

Shi, Zhongwei ^{[29
]}

Sun, Fang ^{[30
]}

Sun, Ningling ^{[24
]}

Tao, Jun ^{[31
]}

Wang, Jiguang ^{[21
,32
]}

Wang, Xinling ^{[33
]}

Wu, Jing ^{[34
]}

Xiao, Xinhua ^{[35
]}

Xie, Liangdi ^{[36
]}

Xu, Jing ^{[37
,38
]}

Ye, Hongying ^{[39
]}

Yu, Dongni ^{[11
]}

Yuan, Hong ^{[40
]}

Zhang, Huijie ^{[41
]}

Zhang, Jian ^{[42
]}

Zhang, Lili ^{[43
]}

Zhang, Yuqing ^{[44
]}

Zhou, Jiaqiang ^{[45
]}

Zhou, Xinli ^{[46
]}

Zhu, Dalong ^{[5
]}

Zhu, Tiehong ^{[46
]}

Li, Sheyu ^{[1
]}

Zhu, Zhiming ^{[2
,3
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Endocrinol & Metab, Chengdu, Peoples R China

[2] Army Med Univ, Chongqing Inst Hypertens, Chongqing, Peoples R China

[3] Chongqing Inst Hypertens, Chongqing, Peoples R China

[4] Shanghai Jiao Tong Univ, Dept Otorhinolaryngol, Peoples Hosp 6, Sch Med, Shanghai, Peoples R China

[5] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Endocrinol, Nanjing, Peoples R China

[6] Peoples Hosp Guangdong Prov, Dept Cardiol, Guangzhou, Peoples R China

[7] Guangzhou Inst Cardiovasc Dis, Guangzhou, Peoples R China

[8] Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu, Peoples R China

[9] Hebei Med Univ, Tangshan City Workers Hosp, Dept Endocrinol, Tangshan 063000, Hebei, Peoples R China

[10] Wuhan Univ, Dept Endocrinol, Renmin Hosp, Wuhan, Peoples R China

[11] Beijing Hosp, Minist Hlth, Dept Endocrinol, Beijing, Peoples R China

[12] China Natl Ctr Bioinformat, Beijing, Peoples R China

[13] Chinese Acad Med Sci, Inst Geriatr, Beijing, Peoples R China

[14] Hebei Gen Hosp, Dept Geriatr Cardiovasc Med, Shijiazhuang, Peoples R China

[15] Gen Hosp Northern Theater Command, Dept Cardiol, Shenyang, Peoples R China

[16] Shenyang Mil Command, Shenyang, Peoples R China

[17] Capital Med Univ, Xuanwu Hosp, Dept Cardiol, Beijing, Peoples R China

[18] Peoples Hosp Xinjiang Uygur Autonomous Reg, Ctr Hypertens, Urumqi, Peoples R China

[19] PLA Rocket Force Characterist Med Ctr, Dept Endocrinol, Beijing, Peoples R China

[20] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Cardiol, Shanghai, Peoples R China

[21] Shanghai Res Inst Hypertens, Shanghai, Peoples R China

[22] Fudan Univ, Huashan Hosp, Dept Cardiol, Shanghai, Peoples R China

[23] Zhengzhou Univ, Affiliated Hosp 1, Dept Endocrinol, Zhengzhou, Peoples R China

[24] Peking Univ Peoples Hosp, Cardiovasc Med Dept, Beijing, Peoples R China

[25] Hebei Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shijiazhuang, Hebei, Peoples R China

[26] Xi An Jiao Tong Univ, Dept Reprod Med, Affiliated Hosp 1, Xian, Peoples R China

[27] Zunyi Med Univ, Dept Cardiovasc Med, Affiliated Hosp, Zunyi, Peoples R China

[28] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Endocrinol & Metab, Shenzhen, Peoples R China

[29] Army Med Univ, Daping Hosp, Army Special Med Ctr, Dept Hypertens & Endocrinol, Chongqing, Peoples R China

[30] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou, Peoples R China

[31] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Hypertens, Shanghai, Peoples R China

[32] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Endocrinol, Urumqi, Peoples R China

[33] Cent South Univ, Dept Endocrinol, Xiangya Hosp, Changsha, Peoples R China

[34] Univ South China, Affiliated Hosp 1, Dept Endocrinol & Metab, Changsha, Peoples R China

[35] Fujian Med Univ, Affiliated Hosp 1, Fuzhou, Peoples R China

[36] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Endocrinol, Xian, Peoples R China

[37] Army Med Univ, Xinqiao Hosp, Dept Endocrinol, Chongqing, Peoples R China

[38] Fudan Univ, Huashan Hosp, Dept Endocrinol, Shanghai, Peoples R China

[39] Cent South Univ, Dept Gynecol, Xiangya Hosp 3, Changsha, Peoples R China

[40] Southern Med Univ, Nanfang Hosp, Dept Endocrinol, Guangzhou, Peoples R China

[41] Hubei Prov Hosp TCM, Dept Encephalopathy, Wuhan, Peoples R China

[42] Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China

[43] Chinese Acad Med Sci, Dept Cardiovasc Surg, Fuwai Hosp, Beijing, Peoples R China

[44] Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Dept Endocrinol & Metab, Hangzhou, Peoples R China

[45] Shandong First Med Univ, Dept Endocrinol & Metab, Shandong Prov Hosp, Jinan, Peoples R China

[46] Tianjin Med Univ, Dept Endocrinol & Metab, Gen Hosp, Tianjin, Peoples R China

来源：

JOURNAL OF EVIDENCE BASED MEDICINE | 2024年 / 17卷 / 04期

基金：

中国国家自然科学基金;

关键词：

anti-hypertensive treatment; blood pressure monitor; hypertension; screening for hypertension; type; 2; diabetes; ALL-CAUSE MORTALITY; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; DISEASE; EFFICACY; SODIUM; HOME; MELLITUS; DYSFUNCTION; INHIBITORS;

D O I：

10.1111/jebm.12655

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Both hypertension and type 2 diabetes are attributable to premature death, cardiovascular and kidney diseases with largely overlapping population. Followed the GRADE approach, this expert consensus aimed to reduce the cardiovascular and kidney death and disability due to hypertension and minimize the treatment burden in adults with type 2 diabetes. Through online survey and discussion, a multidisciplinary team comprehensively prioritized seven key guideline questions. Informed by the evidence synthesis and online discussion, the team developed 12 recommendations under the GRADE Evidence-to-decision (EtD) framework. The recommendations covered the screening of hypertension in adults diagnosed with type 2 diabetes but not hypertension and the monitoring, lifestyle interventions, and medications in those diagnosed with type 2 diabetes and hypertension.

引用

页码：851 / 864

页数：14

共 50 条

[1] Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
Strain, W. David
Down, Su
Brown, Pam
Puttanna, Amar
Sinclair, Alan
DIABETES THERAPY, 2021, 12 (05) : 1227 - 1247
[2] Consensus on the Prevention of Type 2 Diabetes in Chinese Adults
Tong, Yu-Zhen
Tong, Nan-Wei
Teng, Wei-Ping
Mu, Yi-Ming
Zhao, Jia-Jun
Shan, Zhong-Yan
Ning, Guang
CHINESE MEDICAL JOURNAL, 2017, 130 (05) : 600 - 606
[3] Consensus on the Prevention of Type 2 Diabetes in Chinese Adults
Tong Yu-Zhen
Tong Nan-Wei
Teng Wei-Ping
Mu Yi-Ming
Zhao Jia-Jun
Shan Zhong-Yan
Ning Guang
中华医学杂志英文版, 2017, 130 (05) : 600 - 606
[4] Chinese expert consensus on the management of hypertension in the very elderly
Li, Jing
Hu, Yi-Xin
Wang, Wen
Fang, Ning-Yuan
Lu, Xin-Zheng
Pi, Lin
Liu, Mei-Lin
Li, Wei-Min
Li, Yan-Fang
Qu, Peng
Hua, Qi
He, Qing
Wu, Hai-Ying
Zhang, Yuan-Ming
Chen, Xiao-Ping
Chen, Lu-Yuan
Fan, Li
Zhao, Xing-Sheng
Zhu, Zhi-Ming
Jiang, Yi-Nong
Guo, Yi-Fang
Yuan, Hong
Gao, Ping-Jin
Xu, Xin-Juan
Cai, Jun
Xie, Liang-Di
JOURNAL OF GERIATRIC CARDIOLOGY, 2016, 13 (12) : 945 - 953
[5] Effectiveness of a community-based diabetes self-management intervention for Chinese adults with type 2 diabetes: A pilot study
Fu, MinLi
Hu, Jie
Cai, XiaoLi
INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2015, 21 : 132 - 140
[6] Cardiorenal disease management in type 2 diabetes: An expert consensus
Mohan, Viswanathan
Singh, Awadhesh Kumar
Zargar, Abdul Hamid
Almeida, Alan
Bhalla, Anil Kumar
Mohan, Jagadish Chander
Dalal, Jamshed
Sahay, Manisha
Mohanan, Padhinhare P.
Maitra, Sanjay
Ghosh, Sujoy
Jeloka, Tarun
Kaul, Upendra
Sakhuja, Vinay
Das, Mrinal Kanti
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (12)
[7] Assessment and management of hypertension in patients with type 2 diabetes
Thomas, M. C.
Atkins, R.
INTERNAL MEDICINE JOURNAL, 2009, 39 (03) : 143 - 149
[8] Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?
Shahi, Niharika
Tobe, Sheldon W.
CANADIAN JOURNAL OF DIABETES, 2018, 42 (02) : 166 - +
[9] Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League
Liu, Jing
Li, Yan
Zhang, Xinjun
Bu, Peili
Du, Xueping
Fang, Lizheng
Feng, Yingqing
Guo, Yifang
Han, Fei
Jiang, Yinong
Li, Yuming
Lin, Jinxiu
Liu, Min
Liu, Wei
Long, Mingzhi
Mu, Jianjun
Sun, Ningling
Wu, Hao
Xie, Jianhong
Xie, Jingyuan
Xie, Liangdi
Yu, Jing
Yuan, Hong
Zha, Yan
Zhang, Yuqing
Zhu, Shanzhu
Wang, Jiguang
JOURNAL OF CLINICAL HYPERTENSION, 2024, 26 (01): : 71 - 83
[10] Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology
Hong, Tianpei
Su, Qing
Li, Xiaoying
Shan, Zhongyan
Chen, Li
Peng, Yongde
Chen, Liming
Yan, Li
Bao, Yuqian
Lyu, Zhaohui
Shi, Lixin
Wang, Weiqing
Guo, Lixin
Ning, Guang
Mu, Yiming
Zhu, Dalong
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2021, 37 (04)

← 1 2 3 4 5 →